-+ 0.00%
-+ 0.00%
-+ 0.00%

GSK flags availability of Hansoh Pharma update on Ris-Rez phase III China trial results

PUBT·07/10/2026 11:08:10
Listen to the news
GSK flags availability of Hansoh Pharma update on Ris-Rez phase III China trial results
  • GSK posted an update on Hansoh Pharma’s phase III ARTEMIS-008 trial of Ris-Rez in advanced or relapsed small-cell lung cancer in China.
  • Trial met the primary endpoint of overall survival versus topotecan; progression-free survival also improved.
  • GSK holds ex-China rights; global phase III EMBOLD SCLC-301 data in relapsed extensive-stage SCLC are expected next year.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GSK plc published the original content used to generate this news brief on July 10, 2026, and is solely responsible for the information contained therein.